Osteogenesis imperfecta: prospects for molecular therapeutics
about
Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta - A retrospective cohort studyPotential implications of cell therapy for osteogenesis imperfecta.Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta.Persistence of intracellular and extracellular changes after incompletely suppressing expression of the R789C (p.R989C) and R992C (p.R1192C) collagen II mutants.Mutation of the 5'-untranslated region stem-loop structure inhibits α1(I) collagen expression in vivo.Two sets of interacting collagens form functionally distinct substructures within a Caenorhabditis elegans extracellular matrix.Gene therapy approaches for osteogenesis imperfecta.Gene therapy in orthopaedic surgery: the current status.Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspectiveStem cell transplantation before birth - a realistic option for treatment of osteogenesis imperfecta?Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations.Molecular Outcome, Prediction, and Clinical Consequences of Splice Variants in COL1A1, Which Encodes the proα1(I) Chains of Type I Procollagen.Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects.Structural heterogeneity of type I collagen triple helix and its role in osteogenesis imperfecta.Abstracts of the XXVII Italian Society for the Study of Connective Tissues (SISC) Meeting, Bologna, Italy, 8-10 November 2007
P2860
Q33570529-5E798454-5E17-474B-A44A-2B7DB92C54A8Q33674689-FDBCF55B-801B-4C35-9850-76258BF3E40FQ33863266-71C33AC6-14D4-441C-88ED-EFE5734813AFQ34088135-5BCC32A1-45E6-48C6-B4B3-76075913513CQ34312131-496397EC-EDBC-4BC1-BB11-93AE73059012Q34581991-62C99B4B-AB6F-42F9-ABD7-C283274647B1Q34624521-817090FB-AAF0-4EEB-A648-8A29CC036F0DQ34925073-174DC03F-A0BD-4E58-A908-7C17C2634816Q35629569-3EFC44DB-FEE5-4EA5-ADE1-E1965DC3E309Q35630146-338FECB3-081D-4CEE-A984-A807D9BD3A48Q37081787-0D82FD95-3EAF-4D02-AFBD-61E09C7D5B7EQ38472909-913D9086-5443-41AB-9DFF-B0EE455461C7Q38994280-9B86E951-167F-460F-A999-634DCE383D7EQ40950687-63CD581F-CA2F-42B6-92DB-9818B879587FQ45882623-C42F630B-6E02-49A3-86A3-440E1387C88CQ46855555-7625A5B1-A7DF-438A-8D84-0B477D05C6B2Q56996309-27C26F42-FA56-4841-AE54-2232515E78BF
P2860
Osteogenesis imperfecta: prospects for molecular therapeutics
description
2000 nî lūn-bûn
@nan
2000 թուականին հրատարակուած գիտական յօդուած
@hyw
2000 թվականին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Osteogenesis imperfecta: prospects for molecular therapeutics
@ast
Osteogenesis imperfecta: prospects for molecular therapeutics
@en
Osteogenesis imperfecta: prospects for molecular therapeutics
@nl
type
label
Osteogenesis imperfecta: prospects for molecular therapeutics
@ast
Osteogenesis imperfecta: prospects for molecular therapeutics
@en
Osteogenesis imperfecta: prospects for molecular therapeutics
@nl
prefLabel
Osteogenesis imperfecta: prospects for molecular therapeutics
@ast
Osteogenesis imperfecta: prospects for molecular therapeutics
@en
Osteogenesis imperfecta: prospects for molecular therapeutics
@nl
P356
P1476
Osteogenesis imperfecta: prospects for molecular therapeutics
@en
P2093
P304
P356
10.1006/MGME.2000.3039
P407
P577
2000-01-01T00:00:00Z